Disparities in the Availability and Acceptance of Nirsevimab in Massachusetts
- Claire Abraham; Jon Hatoun; Emily Correa; Naveed Rabbani; Louis Vernacchio
Access Resources
About
This research brief examines the differences in how nirsevimab, a treatment for RSV in infants, is available and accepted across Massachusetts. It describes that larger practices with more affluent patients are more likely to offer nirsevimab. Infants from wealthier families or those with complex medical needs were more likely to receive it. Publicly insured infants and those from lower-income areas had less access. The study suggests improving availability for diverse patient groups and educating families about the benefits of immunization to reduce health disparities related to this new treatment option.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.